TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25012707

Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 402

Group type: COMPARATOR
Intervention: 18-gauge needle
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Micropuncture (21-gauge needle) in specific subgroups
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Micropuncture (21-gauge needle)
Number of subjects: 402
Study: 22004983

Group type: EXPERIMENTAL
Intervention: Risperidone plus placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Divalproex plus placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 22
Study: 20143266

Group type: EXPERIMENTAL
Intervention: Breast MRI prior to NAC
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Breast MRI after completion of NAC
Number of subjects: 74
Study: 18391631

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guerin (including a maintenance regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant versus adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens: Methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine and cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorescent light
Number of subjects: 0
Study: 15880333

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3010
Study: 11908598

Group type: EXPERIMENTAL
Intervention: Oleoresin capsicum (OC) spray inhalation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oleoresin capsicum (OC) spray inhalation and Placebo
Number of subjects: 35
Study: 9481626

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement
Number of subjects: 8

Group type: COMPARATOR
Intervention: No pancreatic enzyme replacement
Number of subjects: 8
Study: 8585252

Group type: EXPERIMENTAL
Intervention: Midazolam (mean 5.2 mg i.v.)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Midazolam (mean 4.8 mg) plus pethidin (50 mg)
Number of subjects: 132
Study: 2615928

Group type: EXPERIMENTAL
Intervention: Intravenous administration of d-amphetamine sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 341945

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 46
Study: 31331546

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort) 270‐330 μg tablets three times a day for two months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study: 29950814

Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg (multiple doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Verinurad (2.5-15 mg, single and multiple doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Verinurad (10 mg, multiple doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Verinurad (all doses)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26405232

Group type: EXPERIMENTAL
Intervention: Absorb (bioresorbable vascular scaffold)
Number of subjects: 191

Group type: COMPARATOR
Intervention: EES (durable polymer everolimus-eluting metallic stent)
Number of subjects: 191
Study: 25261674

Group type: EXPERIMENTAL
Intervention: Combined neurolytic block of the celiac and superior hypogastric plexuses
Number of subjects: 52

Group type: COMPARATOR
Intervention: Neurolytic celiac plexus block alone (NCPB group)
Number of subjects: 52
Study: 22238097

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 4 mg of cortisol (hydrocortisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20831787

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 2746

Group type: COMPARATOR
Intervention: Smokers with normal lung function
Number of subjects: 2746

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 2746
Study: 17998771

Group type: EXPERIMENTAL
Intervention: Positive diagnosis of Kawasaki disease
Number of subjects: 9965

Group type: EXPERIMENTAL
Intervention: Electrocardiography and routine echocardiography
Number of subjects: 9965

Group type: EXPERIMENTAL
Intervention: High risk students identified
Number of subjects: 9965
Study: 16321594

Group type: EXPERIMENTAL
Intervention: Added oils and fats intake
Number of subjects: 6572

Group type: EXPERIMENTAL
Intervention: Oils with monounsaturated fatty acids (MUFA)
Number of subjects: 6572

Group type: EXPERIMENTAL
Intervention: Animal fat intake
Number of subjects: 6572

Group type: EXPERIMENTAL
Intervention: Oils with polyunsaturated fatty acids or MUFA
Number of subjects: 6572
Study: 12093240

Group type: EXPERIMENTAL
Intervention: Screened persons for eligibility
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Eligible persons for participation
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Proportion of screened persons who were eligible
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Proportion of eligible persons who enrolled
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Screening process
Number of subjects: 172
Study: 9636831

Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim)-supported FEC therapy (5-fluorouracil, epirubicin, and cyclophosphamide) with ciprofloxacin prophylaxis; nine courses q three weeks; six different FEC dose levels used for treatment.
Number of subjects: 89
Study: 7870397

Group type: EXPERIMENTAL
Intervention: Quantitative cholescintigraphy (QC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Common bile duct dynamics (CBDD)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined TAC and CBDD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Non-invasive QC
Number of subjects: 34
Study: 3348071

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31913967

Group type: EXPERIMENTAL
Intervention: rTMS (25 sessions to the left dorsolateral prefrontal cortex)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ECT (4 to 8 sessions)
Number of subjects: 40
Study: 29452970

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose‐glycerine‐castor oil (CGC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydroxypropyl guar (HPG)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All three treatments (CGC, CMC, HPG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 27898071

Group type: EXPERIMENTAL
Intervention: Active cannabis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 40
Study: 26195541

Group type: EXPERIMENTAL
Intervention: Tailored package (TP) sessions
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 206
Study: 22510538

Group type: COMPARATOR
Intervention: Morphine (60 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Morphine (60 mg/day) + Pregabalin (25 mg/day to 150 mg/day over one week)
Number of subjects: 70
Study: 20850270

Group type: EXPERIMENTAL
Intervention: Pleading invitation e-mail
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Pre-notification e-mail
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Authors published in 2006 or later
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Pre-notification for authors with recent publications
Number of subjects: 569
Study: 18080171

Group type: EXPERIMENTAL
Intervention: Risperidone (0.01-0.08 mg/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol (0.01-0.08 mg/kg/day)
Number of subjects: 30
Study: 16497612

Group type: EXPERIMENTAL
Intervention: AZD3582 375 mg twice daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg twice daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: naproxen 250 mg twice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 75
Study: 12860541

Group type: EXPERIMENTAL
Intervention: Eccentric external and concentric internal peak torques measured at 300 deg/sec in throwers' dominant limb
Number of subjects: 59

Group type: COMPARATOR
Intervention: Eccentric external and concentric internal peak torques measured at 300 deg/sec in nonthrowers' dominant limb
Number of subjects: 59
Study: 11119080

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 4 ppm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation (IRV) with I:E of 1:3, 1:1, and 2:1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of IRV and INO
Number of subjects: 10
Study: 9194508

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Obese patients after adjustment for blood pressure
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Correlation between BMI and mean BP
Number of subjects: 42
Study: 7848156

Group type: EXPERIMENTAL
Intervention: Education on peak flow monitoring (PFM)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Ownership of PEFM
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Self-management plan
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Acquisition of PEFM
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Management decisions based on symptoms
Number of subjects: 352
Study: 2457711

Group type: EXPERIMENTAL
Intervention: BCAA-TPN
Number of subjects: 16
Study: 31953188

Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus neurolysis (EUS‐CPN)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard medicinal treatment using oxycodone and/or fentanyl
Number of subjects: 48
Study: 30427696

Group type: EXPERIMENTAL
Intervention: T'ai chi and qigong (TCQ) training for 1 hour, three times per week for 12 weeks
Number of subjects: 50
Study: 29169378

Group type: EXPERIMENTAL
Intervention: Participatory Theme Elicitation (PTE) analysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Researcher-led analysis
Number of subjects: 8
Study: 24501355

Group type: EXPERIMENTAL
Intervention: Effort-based decision-making task with voluntary choice of more effortful alternative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effort-based decision-making task with forced-choice trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effort-based decision-making task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitively challenging task voluntarily selected
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitively challenging task externally imposed
Number of subjects: 0
Study: 22784841

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg orally)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 20727177

Group type: EXPERIMENTAL
Intervention: Subgrouping for targeted treatment system (multi-component quality improvement intervention including educational courses, outreach visits, audit/feedback, mentoring, and organisational support)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Subgrouping for targeted treatment system
Number of subjects: 1000
Study: 16938152

Group type: EXPERIMENTAL
Intervention: Trachlight lightwand
Number of subjects: 64

Group type: COMPARATOR
Intervention: Eschmann multiple-use introducer
Number of subjects: 64
Study: 16116132

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injections
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11969277

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg intravenous bolus, then 40 mg subcutaneously every 8 h)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 U intravenous bolus, then 30,000 U 24 h(‐1), adjusted to an activated partial thromboplastin time 2‐2.5x normal)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 300
Study: 10817084

Group type: EXPERIMENTAL
Intervention: C. pneumoniae immunoglobulin G levels
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: cytomegalovirus immunoglobulin G levels
Number of subjects: 704
Study: 7911820

Group type: COMPARATOR
Intervention: non-triglyceride-fraction from coffee oil (0.75 g/d for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: purified cafestol (73 mg/d) plus kahweol (58 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oil from Robusta beans (contains cafestol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: coffee oils and brews containing cafestol
Number of subjects: 15
Study: 2756913

Group type: EXPERIMENTAL
Intervention: High-energy supplement
Number of subjects: 108

Group type: COMPARATOR
Intervention: Low-energy supplement
Number of subjects: 108
Study: 5320587

Group type: EXPERIMENTAL
Intervention: Home treatment with griseofulvin
Number of subjects: 395

Group type: COMPARATOR
Intervention: Hospital treatment with griseofulvin
Number of subjects: 395
Study: 31637971

Group type: EXPERIMENTAL
Intervention: Intensive treatment arm
Number of subjects: 8913

Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 8913

Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (≥30 mg/g) versus not
Number of subjects: 8913
Study: 29911802

Group type: EXPERIMENTAL
Intervention: Ephedrine nasal spray
Number of subjects: 20
Study: 26472518

Group type: EXPERIMENTAL
Intervention: Eligible group for omitting ALND according to Z0011 criteria
Number of subjects: 658

Group type: COMPARATOR
Intervention: Ineligible group for omitting ALND according to Z0011 criteria
Number of subjects: 658
Study: 22906039

Group type: EXPERIMENTAL
Intervention: RelyX ARC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maxcem Elite
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (sound teeth)
Number of subjects: 40
Study: 20729010

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) - single face-to-face session
Number of subjects: 418

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 418
Study: 19104900

Group type: EXPERIMENTAL
Intervention: Skin inguinal incision carried out 3-4 cm above the inguinal ligament (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Skin inguinal incision carried out below the inguinal ligament (group B)
Number of subjects: 62
Study: 16713936

Group type: EXPERIMENTAL
Intervention: Intervention clinics with enhanced patient tracking efforts
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Control clinics with standard documentation
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Intervention branch (inactive infants removed)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Intervention branch (inactive infants included)
Number of subjects: 2190
Study: 12457078

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days followed by 10 mg/day)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 10749249

Group type: EXPERIMENTAL
Intervention: Fractal analysis of nuclear medicine images
Number of subjects: 28
Study: 9028719

Group type: EXPERIMENTAL
Intervention: Mexican Americans
Number of subjects: 1276

Group type: COMPARATOR
Intervention: non-Hispanic whites
Number of subjects: 1276
Study: 1587633

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 15
Study: 3710634

Group type: EXPERIMENTAL
Intervention: Aqueous solution (1.0 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rapidly dissolving tablet (1.0 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sustained release product C (1.0 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sustained release product D (1.0 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sustained release product E (1.0 g)
Number of subjects: 6
Study: 29457540

Group type: EXPERIMENTAL
Intervention: CD34+ mononuclear cell therapy (CD34+MCT)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: High CD34+ cell dosage
Number of subjects: 479
Study: 26936844

Group type: EXPERIMENTAL
Intervention: Mission Possible: Parents and Kids Who Listen
Number of subjects: 127

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 127
Study: 25274192

Group type: EXPERIMENTAL
Intervention: Calcium citrate or calcium carbonate (1 g/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Microcrystalline hydroxyapatite (MCH)
Number of subjects: 100
Study: 21941017

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 15°C for 5 minutes after training
Number of subjects: 8
Study: 20233534

Group type: EXPERIMENTAL
Intervention: Layered manual oesophagogastric anastomosis
Number of subjects: 516

Group type: COMPARATOR
Intervention: Stapler oesophagogastric anastomosis
Number of subjects: 516
Study: 18817961

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg) plus Tamsulosin (0.4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine ER plus Tamsulosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16053954

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HF) at 200 ml/kg/h over 8 hours
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration combined with mild hypothermia (HF+HT) at 32 degrees C for 24 hours
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (standard supportive care)
Number of subjects: 61
Study: 12449206

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study: 10498147

Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiography in the occluded IRA group (n = 35)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Filtered QRS duration in the occluded IRA group (n = 35)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: V40 in the occluded IRA group (n = 35)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Patent IRA group (n = 54)
Number of subjects: 89
Study: 8709353

Group type: EXPERIMENTAL
Intervention: Double pigtail ureteral stent
Number of subjects: 194

Group type: COMPARATOR
Intervention: No stent
Number of subjects: 194
Study: 1929823

Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 micrograms injected subcutaneously)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Octreotide acetate
Number of subjects: 9
Study: 6797863

Group type: COMPARATOR
Intervention: Group 1: 40.3 ± 2.0 kcal.kg‐1.day‐1 (7.0 mg glucose.kg‐1.min‐1) and 0.27 ± 0.02 g N.kg‐1.day‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 2: 53.4 ± 6.8 kcal.kg‐1.day‐1 (9.2 mg glucose.kg‐1.min‐1) and 0.36 ± 0.05 g N.kg‐1.day‐1
Number of subjects: 30
Study: 30880321

Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg three times a day for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no CoQ10)
Number of subjects: 30
Study: 29275370

Group type: EXPERIMENTAL
Intervention: Programmable Hypertension Control (PHC) therapy activated after baseline measurements
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional pacing during the Run-In period
Number of subjects: 27
Study: 26672997

Group type: EXPERIMENTAL
Intervention: Ten‐week home‐based intervention according to the Dutch guidelines for occupational therapy in Parkinson's disease
Number of subjects: 124
Study: 24974307

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy skills training (DBT‐ST)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Activities-based support group (ASG)
Number of subjects: 44
Study: 21208581

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 19273785

Group type: EXPERIMENTAL
Intervention: Focal/grid photocoagulation
Number of subjects: 306

Group type: COMPARATOR
Intervention: 1 mg intravitreal triamcinolone
Number of subjects: 306

Group type: COMPARATOR
Intervention: 4 mg intravitreal triamcinolone
Number of subjects: 306
Study: 17905097

Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin A (BTX‐A) injections (100 U or 200 U) followed by cystoscopic hydrodistension
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin A (BTX‐A) injections
Number of subjects: 19
Study: 14971982

Group type: EXPERIMENTAL
Intervention: Combined weights and plyometrics training (2 sessions per week for 8 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal training (Control group, n = 5)
Number of subjects: 11
Study: 11887833

Group type: EXPERIMENTAL
Intervention: Randomized controlled clinical trials (RCCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective observational data
Number of subjects: 0
Study: 9205915

Group type: EXPERIMENTAL
Intervention: e‐PTFE membrane
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: e‐PTFE + HAC
Number of subjects: 18

Group type: COMPARATOR
Intervention: HAC alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: CF
Number of subjects: 18
Study: 8288779

Group type: EXPERIMENTAL
Intervention: 0.5% gold(tri)chloride
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1.0% gold(tri)chloride
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Gold replacement in dentures
Number of subjects: 200
Study: 3675745

Group type: EXPERIMENTAL
Intervention: 100% lactose (LAC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 50% lactose: 50% glucose polymer (LAC + GP)
Number of subjects: 12
Study: 31554519

Group type: EXPERIMENTAL
Intervention: Multidisciplinary quality of life intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 117